Survival after primary and deferred cystectomy for stage T1 transitional cell carcinoma of the bladder

Bedeir Ali-El-Dein, Mohammed S. Al-Marhoon, Mohamed Abdel-Latif, Ahmed Mesbah, Atallah A. Shaaban, Adel Nabeeh, El Housseiny I. Ibrahiem

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Context: The optimal time of cystectomy for nonmuscle invasive bladder cancer (NMIBC) is controversial. Aim: This study aims at comparing cancer-specific survival in primary versus deferred cystectomy for T1 bladder cancer. Settings and Design: Between 1990 and 2004, a retrospective cohort of 204 patients was studied. Materials and Methods: Primary cystectomy at the diagnosis of NMIBC was performed in 134 patients (group 1) and deferred cystectomy was done after failed conservative treatment in 70 (group 2) Both groups were compared regarding patient and tumor characteristics and cancer-specific survival. Statistical Analysis Used: Cancer-specific survival was calculated using the Kaplan-Meier method. Results: Mean follow-up was 79 and 66 months, respectively, in the two groups. Tumor multiplicity was more frequent in group 2; otherwise, both groups were comparable in all characteristics. The definitive stage was T1 in all patients. Although the 3-year (84% in group 1 vs. 79% in group 2), 5-year (78% vs. 71%) and 10-year (69% vs. 64%) cancer-specific survival rates were lower in the deferred cystectomy group, the difference was not statistically significant. In group 2, survival was significantly lower in cases undergoing more than three transurethral resections of bladder tumors (TURBT) than in cases with fewer TURBTs. Conclusions: Cancer-specific survival is statistically comparable for primary and deferred cystectomy in T1 bladder cancer, although there is a non-significant difference in favor of primary cystectomy. In the deferred cystectomy group, the number of TURBTs beyond three is associated with lower survival. Conservative treatment should be adopted for most cases in this category.

Original languageEnglish
Pages (from-to)127-132
Number of pages6
JournalUrology Annals
Volume3
Issue number3
DOIs
Publication statusPublished - Sep 2011

Fingerprint

Transitional Cell Carcinoma
Cystectomy
Urinary Bladder
Urinary Bladder Neoplasms
Survival
Neoplasms
Survival Rate

Keywords

  • Cystectomy
  • deferred
  • non-muscle invasive bladder cancer
  • primary

ASJC Scopus subject areas

  • Urology

Cite this

Ali-El-Dein, B., Al-Marhoon, M. S., Abdel-Latif, M., Mesbah, A., Shaaban, A. A., Nabeeh, A., & Ibrahiem, E. H. I. (2011). Survival after primary and deferred cystectomy for stage T1 transitional cell carcinoma of the bladder. Urology Annals, 3(3), 127-132. https://doi.org/10.4103/0974-7796.84960

Survival after primary and deferred cystectomy for stage T1 transitional cell carcinoma of the bladder. / Ali-El-Dein, Bedeir; Al-Marhoon, Mohammed S.; Abdel-Latif, Mohamed; Mesbah, Ahmed; Shaaban, Atallah A.; Nabeeh, Adel; Ibrahiem, El Housseiny I.

In: Urology Annals, Vol. 3, No. 3, 09.2011, p. 127-132.

Research output: Contribution to journalArticle

Ali-El-Dein, B, Al-Marhoon, MS, Abdel-Latif, M, Mesbah, A, Shaaban, AA, Nabeeh, A & Ibrahiem, EHI 2011, 'Survival after primary and deferred cystectomy for stage T1 transitional cell carcinoma of the bladder', Urology Annals, vol. 3, no. 3, pp. 127-132. https://doi.org/10.4103/0974-7796.84960
Ali-El-Dein, Bedeir ; Al-Marhoon, Mohammed S. ; Abdel-Latif, Mohamed ; Mesbah, Ahmed ; Shaaban, Atallah A. ; Nabeeh, Adel ; Ibrahiem, El Housseiny I. / Survival after primary and deferred cystectomy for stage T1 transitional cell carcinoma of the bladder. In: Urology Annals. 2011 ; Vol. 3, No. 3. pp. 127-132.
@article{6ca3852c32394ac4b0a80f3b558b722e,
title = "Survival after primary and deferred cystectomy for stage T1 transitional cell carcinoma of the bladder",
abstract = "Context: The optimal time of cystectomy for nonmuscle invasive bladder cancer (NMIBC) is controversial. Aim: This study aims at comparing cancer-specific survival in primary versus deferred cystectomy for T1 bladder cancer. Settings and Design: Between 1990 and 2004, a retrospective cohort of 204 patients was studied. Materials and Methods: Primary cystectomy at the diagnosis of NMIBC was performed in 134 patients (group 1) and deferred cystectomy was done after failed conservative treatment in 70 (group 2) Both groups were compared regarding patient and tumor characteristics and cancer-specific survival. Statistical Analysis Used: Cancer-specific survival was calculated using the Kaplan-Meier method. Results: Mean follow-up was 79 and 66 months, respectively, in the two groups. Tumor multiplicity was more frequent in group 2; otherwise, both groups were comparable in all characteristics. The definitive stage was T1 in all patients. Although the 3-year (84{\%} in group 1 vs. 79{\%} in group 2), 5-year (78{\%} vs. 71{\%}) and 10-year (69{\%} vs. 64{\%}) cancer-specific survival rates were lower in the deferred cystectomy group, the difference was not statistically significant. In group 2, survival was significantly lower in cases undergoing more than three transurethral resections of bladder tumors (TURBT) than in cases with fewer TURBTs. Conclusions: Cancer-specific survival is statistically comparable for primary and deferred cystectomy in T1 bladder cancer, although there is a non-significant difference in favor of primary cystectomy. In the deferred cystectomy group, the number of TURBTs beyond three is associated with lower survival. Conservative treatment should be adopted for most cases in this category.",
keywords = "Cystectomy, deferred, non-muscle invasive bladder cancer, primary",
author = "Bedeir Ali-El-Dein and Al-Marhoon, {Mohammed S.} and Mohamed Abdel-Latif and Ahmed Mesbah and Shaaban, {Atallah A.} and Adel Nabeeh and Ibrahiem, {El Housseiny I.}",
year = "2011",
month = "9",
doi = "10.4103/0974-7796.84960",
language = "English",
volume = "3",
pages = "127--132",
journal = "Urology Annals",
issn = "0974-7796",
publisher = "Medknow Publications and Media Pvt. Ltd",
number = "3",

}

TY - JOUR

T1 - Survival after primary and deferred cystectomy for stage T1 transitional cell carcinoma of the bladder

AU - Ali-El-Dein, Bedeir

AU - Al-Marhoon, Mohammed S.

AU - Abdel-Latif, Mohamed

AU - Mesbah, Ahmed

AU - Shaaban, Atallah A.

AU - Nabeeh, Adel

AU - Ibrahiem, El Housseiny I.

PY - 2011/9

Y1 - 2011/9

N2 - Context: The optimal time of cystectomy for nonmuscle invasive bladder cancer (NMIBC) is controversial. Aim: This study aims at comparing cancer-specific survival in primary versus deferred cystectomy for T1 bladder cancer. Settings and Design: Between 1990 and 2004, a retrospective cohort of 204 patients was studied. Materials and Methods: Primary cystectomy at the diagnosis of NMIBC was performed in 134 patients (group 1) and deferred cystectomy was done after failed conservative treatment in 70 (group 2) Both groups were compared regarding patient and tumor characteristics and cancer-specific survival. Statistical Analysis Used: Cancer-specific survival was calculated using the Kaplan-Meier method. Results: Mean follow-up was 79 and 66 months, respectively, in the two groups. Tumor multiplicity was more frequent in group 2; otherwise, both groups were comparable in all characteristics. The definitive stage was T1 in all patients. Although the 3-year (84% in group 1 vs. 79% in group 2), 5-year (78% vs. 71%) and 10-year (69% vs. 64%) cancer-specific survival rates were lower in the deferred cystectomy group, the difference was not statistically significant. In group 2, survival was significantly lower in cases undergoing more than three transurethral resections of bladder tumors (TURBT) than in cases with fewer TURBTs. Conclusions: Cancer-specific survival is statistically comparable for primary and deferred cystectomy in T1 bladder cancer, although there is a non-significant difference in favor of primary cystectomy. In the deferred cystectomy group, the number of TURBTs beyond three is associated with lower survival. Conservative treatment should be adopted for most cases in this category.

AB - Context: The optimal time of cystectomy for nonmuscle invasive bladder cancer (NMIBC) is controversial. Aim: This study aims at comparing cancer-specific survival in primary versus deferred cystectomy for T1 bladder cancer. Settings and Design: Between 1990 and 2004, a retrospective cohort of 204 patients was studied. Materials and Methods: Primary cystectomy at the diagnosis of NMIBC was performed in 134 patients (group 1) and deferred cystectomy was done after failed conservative treatment in 70 (group 2) Both groups were compared regarding patient and tumor characteristics and cancer-specific survival. Statistical Analysis Used: Cancer-specific survival was calculated using the Kaplan-Meier method. Results: Mean follow-up was 79 and 66 months, respectively, in the two groups. Tumor multiplicity was more frequent in group 2; otherwise, both groups were comparable in all characteristics. The definitive stage was T1 in all patients. Although the 3-year (84% in group 1 vs. 79% in group 2), 5-year (78% vs. 71%) and 10-year (69% vs. 64%) cancer-specific survival rates were lower in the deferred cystectomy group, the difference was not statistically significant. In group 2, survival was significantly lower in cases undergoing more than three transurethral resections of bladder tumors (TURBT) than in cases with fewer TURBTs. Conclusions: Cancer-specific survival is statistically comparable for primary and deferred cystectomy in T1 bladder cancer, although there is a non-significant difference in favor of primary cystectomy. In the deferred cystectomy group, the number of TURBTs beyond three is associated with lower survival. Conservative treatment should be adopted for most cases in this category.

KW - Cystectomy

KW - deferred

KW - non-muscle invasive bladder cancer

KW - primary

UR - http://www.scopus.com/inward/record.url?scp=80053081007&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053081007&partnerID=8YFLogxK

U2 - 10.4103/0974-7796.84960

DO - 10.4103/0974-7796.84960

M3 - Article

VL - 3

SP - 127

EP - 132

JO - Urology Annals

JF - Urology Annals

SN - 0974-7796

IS - 3

ER -